Note: in this document any text taken directl y from the protocol is italicized . 2.1.Study Design This is a Phase 1, open label, multi- center, multiple dose, safety, PK, PD and immunogenicity study evaluating the components of a vaccine -based immunotherapy regimen for prostate cancer (PrCa VBIR). PrCa VBIR consists of the following components: Adenovirus (AdC68), pDNA andtremelimumab. In addition, cohorts will evaluate PrCa VBIR when given in combination with PF-06801591 . The study will enroll patients with the following stages of prostate cancer: patients with asymptomatic/minimally symptomat ic metastatic castration -resistant prostate cancer (mCPRC) who have not received secondary hormones (M1 pre- secondary hormones), patients with rising PSA at high risk for recurrence (biochemically relapsed), and asymptomatic/minimally symptomatic mCPRC patients for whom secondary hormone treatment failed (M1 post- secondary hormones). The study is divided in to two parts, D ose Escalation (Part A) followed by D ose Expansion (Part B).